Escalon Medical (ESMC) Receives FDA 510(K) Clearance For VascuView(TM)
More News related to ESMC
- Escalon Medical (ESMC) Sells 1.15M Shares in Private Placement
- Escalon(R) (ESMC) Receives FDA 510(k) Clearance to Market the LIASYS(TM) Clinical Chemistry and Immunoturbidimetric Analyzer
- Escalon Medical (ESMC) Receives FDA 510(K) Clearance For VascuView(TM)
- Escalon Medical (ESMC) Subsidiary Receives FDA 510(k) Clearance
- Escalon Medical (ESMC) Receives FDA 510(K) Clearance for D3 Hematology System
More News related to FDA
- U.S. FDA to Become More Stringent on Medical Imaging Equipment (GE, SI)
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
- Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
- Dynavax Tech (DVAX) Initiates HEPLISAV Phase 3
- Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
Escalon Medical Corp. (Nasdaq: ESMC) today announced that it has received 510(k) clearance from the U.S. FDA to market the VascuView(TM) Visual Ultrasound System for use with assisted vascular access. Its subsidiary, Escalon Vascular Access, Inc., plans to commence shipments of the product in the United States immediately.
Richard J. DePiano Jr., President of Escalon Medical Corp. commented, "The clearance of the VascuView(TM) system is a very promising milestone as it not only reflects the successful culmination of our research and development efforts but represents our third FDA market clearance in the last six weeks. We remain committed to meeting the needs of the clinical community by delivering innovative and cost-effective technologies."
Escalon Medical Corp., together with its subsidiaries, engages in the development, manufacture, marketing, and distribution of medical devices and pharmaceuticals in the areas of ophthalmology, diabetes, hematology, and vascular access.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
